

Mongoose Bio, Inc is a privately held emerging clinical-stage biopharmaceutical company revolutionizing precision oncology with first-in-class T cell receptor T cell (TCR-T) therapies. Leveraging our proprietary and extensive antigen discovery pipeline with memory T cell reprogramming technology, Mongoose Bio is poised to deliver unprecedented coverage of common and rare solid tumors and provide long-lasting immunoprotection.

INVESTMENT HIGHLIGHTS

The science and broad intellectual property behind Mongoose Bio were developed by Dr. Cassian Yee, a leading medical oncologist and faculty member at the renowned MD Anderson Cancer Center in Houston, Texas. Mongoose Bio was spun out of MD Anderson in 2023 and was recently awarded \$10.6M from the Cancer Prevention and Research Institute of Texas (CPRIT).

The Company is preparing to initiate its first Phase 1 study with its lead candidate, MGB-001, in patients with advanced, recurrent/relapsed lung, gastric, and esophageal cancer. Additional programs in the pipeline address other cancers including prostate, triple negative breast, lung, colorectal, bladder and thyroid. The Company has identified one of the leading oncologists at MD Anderson to oversee the Phase 1 study.

Mongoose Bio, backed by 20 years of research in TCR target identification and the epigenetics of T cell memory, has developed a stable of four novel, highly immunogenic targets that are relatively uncharted in the treatment of cancer. The Company has also developed a proprietary technology that extends the life of memory T-cells explicitly modified to kill targeted tumor cells over a sustained period of time. Solving for the lack of novel targets and the inability of T-cells to persist over time, Mongoose Bio is positioned uniquely among oncology focused therapeutic companies.

LEADERSHIP TEAM

Cassian Yee, M.D., Founder, CSO

World renowned medical oncologist and faculty member at the MD Anderson Cancer Center in Houston, Texas. Dr Yee is an Endowed Professor of the Department of Melanoma Medical Oncology and Immunology, Division of Cancer Medicine and Director of the Solid Tumor Cell Therapy Program, Center for Cancer Immunology Research at MDACC.

Neil Warma, M.B.A., President, Chief Executive Officer

Global entrepreneur with over 25 years of proven success in building world class biotech companies in both the public and private markets. Broad international experience in the U.S., Europe and Asia.

FOUNDING INSTITUTION

MD Anderson Cancer Center

The technology was developed under Dr. Yee's guidance at MD Anderson for over 16 years. Mongoose Bio was established in late 2023 with MD Anderson taking an equity stake in the company demonstrating its belief in the potential of the management and the technology to profoundly impact the lives of cancer patients.

The Company has an exclusive license from MD Anderson to develop and commercialize the TCR-T technology worldwide.

FROM THE CEO

“Mongoose Bio is at the forefront of pioneering first-in-class T-cell cancer therapies, leveraging its groundbreaking technology to reprogram T-cells for enhanced persistence and precise targeting of cancer cells, thus offering a promising avenue for effectively eradicating tumor cells. With TCR-T therapies, we are setting new benchmarks and offering significant advancements over traditional CAR-T therapies. This innovative approach not only underscores our commitment to revolutionizing cancer treatment but also positions us to make a substantial impact on the fight against cancer.”

Mongoose Bio

EXPECTED MILESTONES

- 1H '24 Close Seed round
- 2H '24 Pre-IND meeting
- 1H' 25 IND submission
- 1H '25 Phase 1b initiation

FINANCIAL AWARDS/ FUNDING PLAN


- CPRIT award winner: \$10.6M
- Seed round: Closing \$3 M
- Series: \$50 M (2025)

CORPORATE HEADQUARTERS

2450 Holcombe Blvd.,
Suite 200
Houston, TX, 77021

CORPORATE CONTACT

Neil Warma
neil@mongoosebio.com
Tel: +1 281 881 6527



THE PROMISE OF TCR-T

The Problem and Unmet need

The most popular form of adoptive therapy using CAR-T cells achieves complete responses in many patients with B cell malignancies but fails to deliver long-term responses and has been largely unsuccessful for the treatment of solid tumors. **Currently, only 3% of all cancer patients are eligible for T cell therapy.**

Mongoose Bio advances a therapeutic approach that will fulfill the promise of T cell therapy for patients with solid tumors by addressing two major challenges limiting the efficacy and broader applicability of conventional T cell therapy:

1. **Novel targets for TCR-based cell therapy**
2. **T cell persistence**

The Solution and Impact

Mongoose Bio addresses both major challenges by advancing an approach based on TCRs directed against important immunogenic pan-cancer antigens and a memory programming module that will confer *in vivo* longevity to transferred T cells.

1. **Targets for T cell therapy:** TCR-T therapies utilize the T cell receptor (TCR) to engage tumor targets. Because TCRs recognize surface MHC presented fragments of protein (peptides) that can originate from any cellular compartment, TCR targets can be a transcription factor, oncogene, cancer-testis antigen, DNA repair gene, chemoresistance gene or any of the thousands of tumor-associated proteins found in solid tumors. Mongoose Bio has interrogated its database of peptide target spectra and we have selected the highest-ranking antigens for our drug development portfolio.
2. **T cell memory:** The second major challenge to effective T cell therapy has always been the limited persistence *in vivo* of the adoptively transferred T cells, leading to relapse rates as high as 60% despite patients achieving complete remission following CAR-T cell therapy. In large part, this is attributable to the absence of "T cell memory" in the transferred cells – a feature absent from almost every cell therapy modality to date.

Our Competitive Advantage

- **Mongoose Bio accessed 250 highly curated MS-defined epitopes and selected 4 high value targets expressed across several common (lung, breast, prostate, head and neck, bladder, ovarian, colorectal) and rare cancers (gastric, esophageal, chordoma, glioblastoma, anaplastic thyroid cancer).** We expect to have a very broad market share and our strategic plan is to obtain breakthrough status for rare tumor indications in the US, allowing for TCR targets to be shared for common indications globally.
- **The TCR targets chosen by Mongoose Bio were empirically identified by mass spectrometry and validated experimentally for immunogenicity.**
- **The TCRs in Mongoose Bio are *naturally occurring* T cell receptors,** obviating the possibility of target cross-reactivity and requiring no affinity maturation.
- **Mongoose Bio TCR-Therapy uses a clinically proven, epigenetically programmed memory module.** No such memory programming is being developed by any biotech cell therapy company.
- **The memory TCR-T cell product from Mongoose Bio will not require high dose lymphodepletion (vs. all TCR-T and CAR-T companies),** eliminating serious toxicities, permitting outpatient therapy and combinational strategies.